Galectin Therapeutics Inc.

Stage 2 · Advancing · week 2

As of Oct 22, 2026, Galectin Therapeutics is in Stage 2, the uptrend phase, now in week 2 (since Oct 15, 2026). It closed at $3.38, 48.1% below its 52-week high and above its 200-day average, which is falling.

Galectin Therapeutics Inc., a clinical stage biopharmaceutical company, engages in drug development to create new therapies for fibrotic disease and cancer. More about the company

$3.38

+0.30% today

$341M · Small cap

Market Neutral — Building

Pro read

Pro

Our read

In Stage 2, but it has already run

Setup score

—

Momentum

Steady

Edge

—

Setup-score rank among Stage 2 peers: #1 of 110 in Biotechnology · #1 of 272 in Health Care

Is GALT early, or has it already run? Pro answers that for every US stock we cover, after every close.

Get Pro · $19 a month

Renews monthly until you cancel. Cancel any time in Plan & billing.

Loading price chart…

Stage Cycle Timeline2023-08-16 → 2026-10-22

S2 15w

S4 14w

S2 25w

S4 17w

2023-08-162026-10-22

S1S2S3S4Setup score (0–10, dashed line at 5)

S4 2w → S1 1w → S2 15w → S3 8w → S4 2w → S3 1w → S2 15w → S3 9w → S4 2w → S3 1w → S2 13w → S4 14w → S1 7w → S4 6w → S1 4w → S2 25w → S3 6w → S4 17w → S1 7w → S2 5w → S3 3w → S2 1w current

Total tracked: 165 weeks across 22 stage runs.

GALT among Biotechnology301st of 591 by relative strength

All 591 →

Stocks in Biotechnology ranked by relative strength, with stage and one-month change
#	Stock	Stage	RS	1M
1	GTBPGT Biopharma, Inc.	Stage 2 · wk 7	99	−22.3%
2	IOVAIovance Biotherapeutics, Inc.	Stage 2 · wk 18	99	+38.8%
3	SLSSELLAS Life Sciences Group, Inc.	Stage 3 · wk 4	99	−1.5%
4	MRNAModerna, Inc.	Stage 2 · wk 17	99	+11.3%
5	TWSTTwist Bioscience Corporation	Stage 2 · wk 39	99	−14.5%
6	KODKodiak Sciences Inc	Stage 2 · wk 4	99	+172.1%
7	ERASErasca, Inc.	Stage 3 · wk 5	99	+0.7%
8	CLYMClimb Bio, Inc.	Stage 3 · wk 3	99	−15.8%
…301	GALTGalectin Therapeutics Inc.	Stage 2 · wk 2	30	−16.5%

vs 52W High

-48.1%

$2.08 lo$6.51 hi

48.1% below 52W high

How far this stock is from its 52-week high. A pullback of 3–20% while Stage 2 structure holds is typically a better entry than chasing near the high.

Stage Maturity

Week 2

1w13w26w

Week 2, fresh breakout

How long this stock has been in Stage 2. The sweet spot is mid-run: long enough to prove the structure holds, not so long that it's extended. Very fresh moves (weeks 1–4) often need more time to confirm.

vs 200 DMA

5.5%

200 DMA: $3.20 · sloping down

Long-term trend anchor. When the stock and the S&P 500 are both above their 200-day averages, the backdrop supports continuation.

Rel Volume

0.56x

vs 50-day avg

Low vol (0.5–1x) on pullbacks = resting, not being sold. High vol on breakouts = commitment. Volume spike on down days is a warning sign.

Trend Health

↓

Short-term trend rolling over

Two reads of momentum. The arrow shows the direction of the short-term trend: rising (↑ or ↗), flat (→) or rolling over (↓). The ⇈ mark appears when our trend model reads the move as gaining speed on top of the longer trend. Strongest when both agree.

-16.5%

-2.6%

+42.6%

YTD

-16.5%

-36.2%

Scan Membership

Breakout Watch

Latest: 2024-09-13

10 appearances in last 60 days. First seen: 2018-10-25.

A stock that keeps qualifying week after week does so because its Stage 2 structure keeps holding. Staying power in the scan says more about the trend than any single appearance.

Recent Stage Timeline

2026-10-22S2

Wk 2 · Vol 0.56x

2026-10-21S2

Wk 1 · Vol 0.96x

2026-10-20S2

Wk 1 · Vol 0.69x

2026-10-19S2

Wk 1 · Vol 0.60x

2026-10-16S2

Wk 1 · Vol 0.56x

2026-10-15S23→2

Wk 1 · Vol 0.39x

2026-10-14S3

Wk 3 · Vol 1.31x

2026-10-13S3

Wk 3 · Vol 0.58x

2026-10-12S3

Wk 3 · Vol 0.31x

2026-10-09S3

Wk 3 · Vol 0.48x

2026-10-08S3

Wk 3 · Vol 0.83x

2026-10-07S3

Wk 2 · Vol 0.53x

Moving averages & range

50 DMA

$3.84

200 DMA

$3.20

52W High

$6.51

52W Low

$2.08

5D Low

$3.37

Resistance levels (recent highs)

20d High

$3.94

60d High

$4.61

120d High

$5.34

250d High

$6.51

Next resistance

+16.6%

to 20d High

Dividend Yield

0.00%

P/B -1.6

Galectin Therapeutics: quick answers

What stage is Galectin Therapeutics in?

As of Oct 22, 2026, Galectin Therapeutics (GALT) is in Stage 2, the uptrend phase. It entered Stage 2 on Oct 15, 2026 and is in week 2. What the four stages mean

Is Galectin Therapeutics in an uptrend?

Yes. Galectin Therapeutics is in a Stage 2 uptrend. It trades 5.5% above its 200-day average, which is falling.

How far is Galectin Therapeutics from its 52-week high?

Galectin Therapeutics closed at $3.38 on Oct 22, 2026, 48.1% below its 52-week high of $6.51. Its 52-week low is $2.08.

How has Galectin Therapeutics performed over the past year?

As of Oct 22, 2026, Galectin Therapeutics is down 36.2% over the past year and down 16.5% so far in 2026.

Which sector and industry is Galectin Therapeutics in?

Galectin Therapeutics is in the Biotechnology industry, part of the Health Care sector.

About this companyHealth Care· Biotechnology

Galectin Therapeutics Inc., a clinical stage biopharmaceutical company, engages in drug development to create new therapies for fibrotic disease and cancer. The company's lead product candidate is belapectin (GR-MD-02), a galectin-3 inhibitor, which is in a Phase 2 clinical study in MASH patients with advanced fibrosis and a second Phase 2b clinical trial in MASH patients with compensated cirrhosis and portal hypertension. It has a joint venture co-owned by SBH Sciences, Inc. to research and develop small organic molecule inhibitors of galectin-3 for oral administration. The company was formerly known as Pro-Pharmaceuticals, Inc. and changed its name to Galectin Therapeutics Inc. in May 2011. Galectin Therapeutics Inc. was founded in 2000 and is based in Norcross, Georgia.

Visit company website →

All analytics based on EOD data. Data as of 2026-10-22. Past data patterns are not indicative of future results. This page is a data analytics tool only.